Back

ESC recommendations for the use of SGLT2i, GLP-1 RA, mineralocorticoid receptor antagonists, and angiotensin receptor neprilysin inhibitor in the management of heart failure with mildly reduced or preserved ejection fraction

29 August 2026 (18:00 - 18:15)
Organised by: Logo
Congress Presentation Part of: Pharmacologic management of heart failure with mildly reduced or preserved ejection fraction Treatment ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Rudolf De Boer

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
Canadian recommendations for the use of SGLT2i and mineralocorticoid receptor antagonists in the management of heart failure with mildly reduced or preserved ejection fraction
Doctor M. Davis (Vancouver, CA)
Slides Video
Presentation thumbnail
Canadian recommendations for the use of angiotensin receptor neprilysin inhibitor and GLP-1 RA in the management of heart failure with mildly reduced or preserved ejection fraction
Doctor S. Zieroth (Winnipeg, CA)
Slides Video
Presentation thumbnail
What is the horizon for heart failure with mildly reduced or preserved ejection fraction?
Professor J. McMurray (Glasgow, GB)
Slides Video

Access the full session

Session thumbnail
Pharmacologic management of heart failure with mildly reduced or preserved ejection fraction
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 18:00 CET
You may be interested in
thumbnail
Congress Session
2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – Ask the Guidelines Task Force
27 August 2023
thumbnail
Congress Presentation
State-of-the-art lecture on contemporary therapy for HFrEF
28 August 2026
thumbnail
Congress Presentation
Heart failure with 'preserved' EF: what is a 'preserved' EF and how should I treat these patients?
28 August 2022
thumbnail
Congress Presentation
2026 ESC Guidelines for the Management of Heart Failure
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources